What question did this study set out to answer?

To identify molecular and clinical characteristics of IDH mutant MDS and the implications for targeted therapies.

December 8, 2025BloodOpen Access

IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies

View Full Paper

Ask AI

Bookmark

Authors

Observational study highlights unique clinical features and somatic mutations in IDH mutant MDS, suggesting targeted therapies may improve outcomes.

To identify molecular and clinical characteristics of IDH mutant MDS and the implications for targeted therapies.
Identified patients with IDH1 and IDH2 somatic mutations and compared them to wildtype IDH cohorts.
Examined baseline characteristics, overall survival, AML transformation, and response to therapy.
Utilized statistical analyses to evaluate differences between groups.
Among 3513 MDS patients, 3% had IDH1 and 4.4% had IDH2 mutations.
IDH mutant patients had higher risk scores and specific somatic mutations compared to wildtype patients.
Treatment with IDH inhibitors was associated with better overall survival compared to those who did not receive treatment.

Azem et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Observational study highlights unique clinical features and somatic mutations in IDH mutant MDS, suggesting targeted therapies may improve outcomes.

To identify molecular and clinical characteristics of IDH mutant MDS and the implications for targeted therapies.
Identified patients with IDH1 and IDH2 somatic mutations and compared them to wildtype IDH cohorts.
Examined baseline characteristics, overall survival, AML transformation, and response to therapy.
Utilized statistical analyses to evaluate differences between groups.
Among 3513 MDS patients, 3% had IDH1 and 4.4% had IDH2 mutations.
IDH mutant patients had higher risk scores and specific somatic mutations compared to wildtype patients.
Treatment with IDH inhibitors was associated with better overall survival compared to those who did not receive treatment.

Azem et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark